| Drug General Information |
| Drug ID |
D0Y7QZ
|
| Former ID |
DNC010638
|
| Drug Name |
4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H16N4
|
| Canonical SMILES |
CC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC4=CC=CC=C4N=C3
|
| InChI |
1S/C20H16N4/c1-14-6-8-17(9-7-14)23-20-21-11-10-19(24-20)16-12-15-4-2-3-5-18(15)22-13-16/h2-13H,1H3,(H,21,23,24)
|
| InChIKey |
DLSCDFDGOMZHSD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
G2/mitotic-specific cyclin B1 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cell division control protein 2 homolog |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
FoxO signaling pathway
|
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
Progesterone-mediated oocyte maturationhsa04110:Cell cycle
|
|
Gap junction
|
|
Progesterone-mediated oocyte maturation
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_21:RANKL Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Validated targets of C-MYC transcriptional activation
|
|
PLK1 signaling events
|
|
FoxO family signaling
|
|
Direct p53 effectors
|
|
FOXM1 transcription factor network
|
|
C-MYB transcription factor networkp73pathway:p73 transcription factor network
|
|
E2F transcription factor network
|
|
AP-1 transcription factor network
|
|
Retinoic acid receptors-mediated signaling
|
|
Reactome
|
Polo-like kinase mediated events
|
|
Golgi Cisternae Pericentriolar Stack Reorganization
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
Phosphorylation of the APC/C
|
|
Phosphorylation of Emi1
|
|
Condensation of Prophase Chromosomes
|
|
MASTL Facilitates Mitotic Progression
|
|
Resolution of Sister Chromatid Cohesion
|
|
Condensation of Prometaphase Chromosomes
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
|
Recruitment of NuMA to mitotic centrosomes
|
|
Depolymerisation of the Nuclear Lamina
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
G2/M DNA replication checkpoint
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-110056:MAPK3 (ERK1) activation
|
|
E2F mediated regulation of DNA replication
|
|
G0 and Early G1
|
|
Cyclin B2 mediated events
|
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
|
Loss of Nlp from mitotic centrosomes
|
|
Recruitment of mitotic centrosome proteins and complexes
|
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
|
Anchoring of the basal body to the plasma membrane
|
|
MAPK6/MAPK4 signaling
|
|
G1/S-Specific Transcription
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Mitotic Prophase
|
|
Mitotic Prometaphase
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage Response
|
|
AMPK SignalingWP707:DNA Damage Response
|
|
TGF beta Signaling Pathway
|
|
PPAR Alpha Pathway
|
|
MAP kinase activation in TLR cascade
|
|
RAF/MAP kinase cascade
|
|
BMI1
|
|
Spinal Cord Injury
|
|
Prostate Cancer
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Cancer pathway
|
| References |
| REF 1 | Eur J Med Chem. 2010 Jan;45(1):379-86. Epub 2009 Oct 13.Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. |
|---|
